DPYD Gene Testing
The DPYD gene creates dihydropyrimidine dehydrogenase (DPD) enzymes that interact with medications commonly used in chemotherapy for cancer. Like many genes, mutations and variations can change how individuals react to treatments. That is why if a patient knows their family has a history of adverse reactions to specific medications or have experienced side effects or issues with medications linked to a specific gene they should consider getting genetic testing.
Pharmacogenetic Data For Cancer Treatments
When starting any drug therapy, it is vital to understand a variety of factors. A patient’s age, gender, weight, and family history, are all important factors that mitigate how they may respond to treatment. However, recent developments have now provided a much more effective tool for predicting patient reactions to medication. Pharmacogenetics testing can help patients avoid adverse reaction and medication inefficacy. There are over 250 medications that FDA has decided to add important pharmacogenetic information to their labels. These medications include cancer treatments.
Genetic Testing for Xeloda® & Adrucil®
Both Xeloda (capecitabine) and Adrucil (fluorouracil) are commonly used in chemotherapy. Both of these medications have been linked both to the DPYD gene and specifically have noted pharmacogenetic factors that influence treatment. In fact many cancer treatments are affected by an individual’s genetics. For this reason, it is recommended that any patients who have a family history of adverse reactions or are concerned about potential issues with chemotherapy consider PGx testing.